Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON, Canada.
Mol Pharmacol. 2010 Apr;77(4):644-59. doi: 10.1124/mol.109.059410. Epub 2010 Jan 5.
Pharmacotherapy of brain HIV-1 infection may be limited by ABC transporters [i.e., P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1)] that export antiretroviral drugs from HIV-1 brain cellular targets (i.e., astrocytes, microglia). Using an in vitro astrocyte model of an HIV-1 associated inflammatory response, our laboratory has shown that cytokines [i.e., tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1 beta, IL-6], which are secreted in response to HIV-1 envelope glycoprotein gp120 exposure, can decrease P-gp functional expression; however, it is unknown whether these same cytokines can alter expression and/or activity of other ABC transporters (i.e., Mrp1). In primary cultures of rat astrocytes, Mrp1 expression was increased by TNF-alpha (2.7-fold) but was not altered by IL-1 beta or IL-6. Cellular retention of 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, an Mrp substrate, was reduced in TNF-alpha-treated astrocytes, suggesting increased Mrp-mediated transport. Pharmacologic inhibition of nuclear factor-kappaB (NF-kappaB) signaling with SN50 prevented both TNF-alpha release and Mrp1 expression changes in astrocytes triggered with gp120; however, SN50 did not attenuate Mrp1 expression in cells triggered with TNF-alpha. In contrast, Mrp1 functional expression was not altered in the presence of gp120 or TNF-alpha when astrocyte cultures were pretreated with 1,9-pyrazoloanthrone (SP600125), an established c-Jun N-terminal kinase (JNK) inhibitor. SP600125 did not affect TNF-alpha release from cultured astrocytes triggered with gp120. Mrp1 mRNA expression was increased after treatment with gp120 (1.6-fold) or TNF-alpha (1.7-fold), suggesting altered Mrp1 gene transcription. These data suggest that gp120 and TNF-alpha can up-regulate Mrp1 expression in cultured astrocytes. Furthermore, our results imply that both NF-kappaB and JNK signaling are involved in Mrp1 regulation during an HIV-1 associated inflammatory response.
抗逆转录病毒药物从 HIV-1 脑内靶细胞(如星形胶质细胞、小胶质细胞)中输出的 ABC 转运蛋白(如 P-糖蛋白 [P-gp]、多药耐药蛋白 1 [Mrp1])可能会限制脑 HIV-1 感染的药物治疗。我们实验室使用星形胶质细胞体外模型研究了 HIV-1 相关炎症反应,结果表明,细胞因子(如肿瘤坏死因子-α [TNF-α]、白细胞介素-1β [IL-1β]、白细胞介素-6 [IL-6])在 HIV-1 包膜糖蛋白 gp120 暴露时分泌,可降低 P-gp 的功能表达;但是,尚不清楚这些相同的细胞因子是否会改变其他 ABC 转运蛋白(如 Mrp1)的表达和/或活性。在原代培养的大鼠星形胶质细胞中,TNF-α使 Mrp1 表达增加了 2.7 倍,但 IL-1β或 IL-6 没有改变。TNF-α 处理的星形胶质细胞中,2',7'-双(2-羧乙基)-5-(和-6)-羧基荧光素(Mrp 底物)的细胞内保留减少,表明 Mrp 介导的转运增加。用 SN50 抑制核因子-κB(NF-κB)信号转导可防止 gp120 触发的星形胶质细胞中 TNF-α 的释放和 Mrp1 表达变化;但是,SN50 不能减轻 TNF-α 触发的细胞中 Mrp1 的表达。相反,当星形胶质细胞培养物用 1,9-吡唑并蒽酮(SP600125)预处理时,gp120 或 TNF-α存在时,Mrp1 功能表达没有改变,SP600125 不影响 gp120 触发的培养星形胶质细胞中 TNF-α 的释放。用 gp120(1.6 倍)或 TNF-α(1.7 倍)处理后,Mrp1 mRNA 表达增加,提示 Mrp1 基因转录改变。这些数据表明,gp120 和 TNF-α 可在上皮细胞中上调 Mrp1 表达。此外,我们的结果表明,NF-κB 和 JNK 信号通路均参与 HIV-1 相关炎症反应期间的 Mrp1 调节。